 Home > Active Ingredient News > Antitumor Therapy > NEJM: How effective is pembrolizumab in treating persistent, recurrent or metastatic cervical cancer?

NEJM: How effective is pembrolizumab in treating persistent, recurrent or metastatic cervical cancer?

 Last Update: 2021-12-04
 Source: Internet
 Author: User

Tags

acute cervical strain

phase 4 stereo

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Pembrolizumab is effective against programmed death ligand 1 (PD-L1) positive metastatic or unresectable cervical cancer that progressed during chemotherapy

Recently, a research article published in the top medical journal NEJM, researchers aimed to evaluate the relative benefits of adding pembrolizumab to chemotherapy regimens with or without bevacizumab

In this double-blind phase 3 trial, researchers randomly assigned patients with persistent, recurrent, or metastatic cervical cancer at a 1:1 ratio to receive pembrolizumab (200mg) or placebo every 3 weeks , Up to 35 cycles of platinum-based chemotherapy

Among the 548 patients with a PD-L1 composite positive score of 1 or higher, the median progression-free survival in the pembrolizumab group was 10.

It can be seen that in patients with persistent, recurrent or metastatic cervical cancer who received chemotherapy with or without bevacizumab, the progression-free survival and overall survival of the pembrolizumab group were significantly longer than those of the placebo group

In patients with persistent, recurrent, or metastatic cervical cancer who received chemotherapy with or without bevacizumab, the progression-free survival and overall survival of the pembrolizumab group were significantly longer than those of the placebo group

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.